Carotid Sinus Stimulation for Hypertension

Number: 0820

Table Of Contents

Policy
Applicable CPT / HCPCS / ICD-10 Codes
Background
References

---

Policy

Scope of Policy

This Clinical Policy Bulletin addresses carotid sinus stimulation for hypertension.

Experimental and Investigational

1. Aetna considers implantable carotid sinus stimulators (e.g., the Barostim neo™ System, and the Rheos Baroreflex Hypertension Therapy System) experimental and investigational for the treatment of hypertension and for all other indications (e.g., heart failure) because its effectiveness has not been established.
2. Aetna considers magnetic stimulation of carotid sinus experimental and investigational for the treatment of hypertension because its effectiveness has not been established.

---

Table:

CPT Codes / HCPCS Codes / ICD-10 Codes

Code	Code Description
Information in the [brackets] below has been added for clarification purposes.   Codes requiring a 7th character are represented by "+":
CPT codes not covered for indications listed in the CPB:
0266T	Implantation or replacement of carotid sinus baroreflex activation device; total system (includes generator placement, unilateral or bilateral lead placement, intra-operative interrogation, programming and repositioning, when performed)
0267T	Implantation or replacement of carotid sinus baroreflex activation device; lead only (includes intra-operative interrogation, programming and repositioning, when performed)
0268T	Implantation or replacement of carotid sinus baroreflex activation device; pulse generator only (includes intra-operative interrogation, programming and repositioning, when performed)
0269T	Revision or removal of carotid sinus baroreflex activation device; total system (includes generator placement, unilateral or bilateral lead placement, intra-operative interrogation, programming and repositioning, when performed)
0270T	Revision or removal of carotid sinus baroreflex activation device; lead only (includes intra-operative interrogation, programming and repositioning, when performed)
0271T	Revision or removal of carotid sinus baroreflex activation device; pulse generator only (includes intra-operative interrogation, programming and repositioning, when performed)
0272T	Interrogation device evaluation (in person), carotid sinus baroreflex activation system, including telemetric iterative communications with the implantable device to monitor device diagnostics and programmed therapy values, with interpretation and report (eg, battery status, lead impedance, pulse amplitude, pulse width, therapy frequency, pathway mode, burst node, therapy start/stop times each day)
0273T	Interrogation device evaluation (in person), carotid sinus baroreflex activation system, including telemetric iterative communications with the implantable device to monitor device diagnostics and programmed therapy values, with interpretation and report (eg, battery status, lead impedance, pulse amplitude, pulse width, therapy frequency, pathway mode, burst node, therapy start/stop times each day) with programming
HCPCS codes not covered for indications listed in the CPB:
C1825	Generator, neurostimulator (implantable), non-rechargeable with carotid sinus baroreceptor stimulation lead(s)
ICD-10 codes not covered for indications listed in the CPB (not all-inclusive):
I10 - I16.2	Hypertensive diseases
I50.1 - I50.9	Heart failure

---

Background

Hypertension is a major cause of morbidity and mortality in the United States.  Despite the availability of potent anti-hypertensive medications, many patients remain hypertensive.  Thus, non-pharmacological therapies have been attracting more interest.  Electrical stimulation (ES) of the carotid sinus has been shown to lowers blood pressure (BP) by activating the baroreflex and thereby reducing sympathetic tone.  The arterial baroreflex regulates mean arterial pressure by responding automatically to changes in cardiac output and vessel tone via baroreceptors, which monitor arterial pressure by gauging the degree of stretch in vessel walls.  Baroreceptors are located in the walls of the aorta and carotid arteries, with a concentration of receptors located within the carotid sinus.  Activation of baroreceptors produces immediate responses in cardiovascular sympathetic and cardiac parasympathetic nerves to adjust heart rate (HR), stroke volume, vasoconstriction, as well as fluid excretion.  These actions raise or lower BP as needed.

The Rheos Baroreflex Hypertension Therapy System (CVRx, Inc., Minneapolis, MN) is an implantable device for the treatment of patients with drug-resistant hypertension (i.e., the hypertensive state characterized by the inability of multiple anti-hypertensive drug interventions to lower BP to goal levels) who have a systolic BP (SBP) of greater than or equal to 160 mm Hg.  It is reported to reduce BP by activating the baroreflex through ES of baroreceptors in the carotid sinus.  The Rheos Baroreflex Hypertension Therapy System has 3 major components:

• An implantable pulse generator (IPG)
• Carotid sinus leads (CSLs)
• A programmer system.

The pulse generator is implanted subcutaneously near the collarbone.  The CSLs are placed on the carotid arteries and run subcutaneously to the pulse generator (Note: the procedure does not involve carotid dissection).  The operation usually takes about 2 to 3 hours.  After implantation, a continuous mild electrical pulsation stimulates baroreceptors to produce a reflexive reduction in BP.  The IPG provides control and delivery of activation energy through the CSLs.  The leads conduct activation energy from the IPG to target receptors in the left and right carotid arteries.  The programmer system provides the ability to communicate non-invasively with the IPG after implantation to modulate the frequency and intensity of ES.

In a phase II clinical trial, Illig et al (2006) evaluated the response of patients with multidrug-resistant hypertension to ES of the carotid sinus via an implantable device.  The system consists of an IPG with bilateral peri-vascular CSLs.  Implantation was performed bilaterally with patients under narcotic anesthesia.  Dose-response testing at 0 to 6 V was assessed before discharge and at monthly intervals thereafter; the device was activated after 1 month's recovery time.  This was a Food and Drug Administration-monitored phase II trial performed at 5 centers in the United States.  A total of 10 patients with resistant hypertension (taking a median of 6 anti-hypertensive medications) underwent implantation.  All 10 were successful, with no significant morbidity.  The mean procedure time was 198 minutes.  There were no adverse events attributable to the device.  Pre-discharge dose-response testing revealed consistent (r = 0.88) reductions in SBP of 41 mm Hg (mean fall is from 180 to 139 mm Hg), with a peak response at 4.8 V (p < 0.001) and without significant bradycardia or bothersome symptoms.  The authors concluded that a surgically implantable device for ES of the carotid baroreflex system can be placed safely and produces a significant acute decrease in BP without significant side effects.

Tordoir et al (2007) examined peri-operative outcomes and BP responses to an implantable carotid sinus baroreflex activating system being investigated for the treatment of drug-resistant hypertension.  These investigators reported on the first 17 patients enrolled in a multi-center study.  Bilateral peri-vascular CSLs and a IPG are permanently implanted.  Optimal placement of the CSL is determined by intra-operative BP responses to test activations.  Acute BP responses were tested post-operatively and during the first 4 months of follow-up.  Prior to implant, BP was 189.6 +/- 27.5 (SBP)/110.7 +/- 15.3 (diastolic BP [DBP]) mm Hg despite stable therapy (5.2 +/- 1.8 anti-hypertensive drugs).  The mean procedure time was 202 +/- 43 minutes.  No peri-operative strokes or deaths occurred.  System tests performed 1 or up to 3 days post-operatively resulted in significant (all p < or = 0.0001) mean maximum reduction, with standard deviations and 95 % confidence limits for SBP, DBP and HR of 28 +/- 22 (17, 39) mm Hg, 16 +/- 11 (10, 22) mm Hg and 8 +/- 4 (6, 11) beats/min, respectively.  Repeated testing during 3 months of therapeutic electrical activation demonstrated a durable response.  The authors concluded that these preliminary data suggest an acceptable safety of the procedure with a low rate of adverse events and support further clinical development of baroreflex activation as a new concept to treat resistant hypertension.

Heusser et al (2010) tested the hypothesis that ES of carotid baroreceptors acutely reduces sympathetic vasomotor tone and BP in patients with drug-resistant arterial hypertension.  Furthermore, these researchers tested whether ES impairs the physiological baroreflex regulation.  They studied 7 men and 5 women (aged 43 to 69 years) with drug-resistant arterial hypertension.  A bilateral electric baroreflex stimulator at the level of the carotid sinus (Rheos) was implanted greater than or equal to 1 month before the study.  Intra-arterial BP, HR, muscle sympathetic nerve activity (micro-neurography), cardiac baroreflex sensitivity (cross-spectral analysis and sequence method), sympathetic baroreflex sensitivity (threshold technique), plasma renin, and norepinephrine concentrations were measured.  Measurements were performed under resting conditions, with and without electric baroreflex stimulation, for greater than or equal to 6 minutes during the same experiment.  Intra-arterial BP was 193 +/- 9/94 +/- 5 mm Hg on medications.  Acute electric baroreflex stimulation decreased SBP by 32 +/- 10 mm Hg (range of +7 to -108 mm Hg; p = 0.01).  The depressor response was correlated with a muscle sympathetic nerve activity reduction (r(2) = 0.42; p < 0.05).  In responders, muscle sympathetic nerve activity decreased sharply when ES started.  Then, muscle sympathetic nerve activity increased but remained below the baseline level throughout the stimulation period.  Heart rate decreased 4.5 +/- 1.5 beats/min with ES (p < 0.05).  Plasma renin concentration decreased 20 +/- 8 % (p < 0.05).  Electrical stimulation of carotid sinus baroreflex afferents acutely decreased arterial BP in hypertensive patients, without negative effects on physiological baroreflex regulation.  The depressor response was mediated through sympathetic inhibition.

Sanchez et al (2010) evaluated carotid artery structural integrity after implantation of the CSLs.  A total of 29 CSLs were implanted on the common carotid arteries of 8 sheep.  The studies were terminated at 3 and 6 months post-implantation to assess anatomical and histological changes.  Additionally, 10 patients with resistant hypertension were enrolled in the Rheos Multicenter Feasibility Trial.  Duplex ultrasound (DUS) was performed before device implantation and at 1 and 4 months post-implantation in this patient cohort.  An independent core laboratory assessed all DUSs.  Ovine carotid angiography revealed no significant stenoses, while anatomical and histological evaluations demonstrated electrode encapsulation in a thin layer of connective tissue with no evidence of stenosis, erosion, or inflammation.  Duplex ultrasound evaluation revealed no significant increase in peak systolic velocities of the common and internal carotid arteries 1 and 4 months after initial implantation, indicating a lack of injury, remodeling, or stenosis.  The authors concluded that the current data suggested that the CSLs used with the Rheos System are not associated with the development of carotid stenosis or injury.  These short-term data support the concept of CSL placement and merit long-term investigation in a larger multi-center prospective trial.

In a prospective, non-randomized, feasibility study, Scheffers et al (2010) examined the safety and efficacy of Rheos therapy in drug-resistant hypertension patients.  A total of 45 subjects with SBP greater than or equal to 160 mm Hg or DBP greater than or equal to 90 mm Hg despite at least 3 anti-hypertensive drugs were enrolled in this study.  Subjects were followed-up for as long as 2 years.  An external programmer was used to optimize and individualize efficacy.  Baseline mean BP was 179/105 mm Hg and HR was 80 beats/min, with a median of 5 anti-hypertensive drugs.  After 3 months of device therapy, mean BP was reduced by 21/12 mm Hg.  This result was sustained in 17 subjects who completed 2 years of follow-up, with a mean reduction of 33/22 mm Hg.  The device exhibited a favorable safety profile.  The authors concluded that the Rheos device sustainably reduces BP in drug-resistant hypertensive subjects with multiple co-morbidities receiving numerous medications.  They stated that this novel approach holds promise for patients with drug-resistant hypertension and is currently under evaluation in a prospective, placebo-controlled clinical trial.

Doumas et al (2009) stated that the role of the carotid baroreflex in BP regulation has been known for a long time but its effects were thought to be short-lived.  Recent data indicate that stimulation of carotid baroreceptors may lower BP not only for short periods of time, but also in the long run.  Recent advances in technology permitted the development of a new device (Rheos) that addresses problems with older devices.  Several questions remain to be addressed before Rheos can be used widely, and several potential clinical applications remain to be clarified.  The authors stated that the carotid baroreceptor reflex is probably not completely in control of BP.  Baroreflexes are one of many control systems acting in concert.  Joshi and associates (2009) stated that ES of the carotid sinus baroreceptor through a surgically implanted device is currently under clinical investigation and is showing some encouraging early results.  Furthermore, Lovett et al (2009) noted that chronic results from feasibility studies indicated that Rheos therapy has an acceptable safety profile and may lead to long-term control of BP in drug-resistant hypertensive patients.  Other effects include significant reductions in left ventricular mass and left atrial size.  The spectrum of therapeutic impact suggests that Rheos therapy may improve long-term outcomes in drug-resistant hypertension and possibly benefit related populations.  They noted that larger randomized, controlled trials are ongoing to verify chronic benefits.

Lohmeier and Iliescu (2011) summarized the pre-clinical studies that have provided insight into the mechanisms that account for the chronic BP-lowering effects of carotid baroreflex activation.  Some of the mechanisms identified were predictable and confirmed by experimentation.  Others have been surprising and controversial, and resolution will require further investigation.  They stated that although feasibility studies have been promising, firm conclusions regarding the value of this device-based therapy for the treatment of drug-resistant hypertension awaits the results of current multi-center trials.  Ng and colleagues (2011) noted that the Rheos Baroreflex Hypertension Therapy System is a new implantable device that can treat patients with hypertension resistant to multi-drug therapy, by activating the carotid baroreflex through ES of the carotid sinus wall.  Recent studies in both normotensive and hypertensive canine models have reported sustained and clinically relevant reductions in arterial pressure and sympathetic activity with prolonged baroreflex activation.  Clinical trials designed to evaluate the safety and effectiveness of this therapy in patients with drug-resistant hypertension, are now ongoing in both Europe and the United States.

In a single-arm, open-label study, Hoppe and associates (2012) evaluated the effectiveness of the Barostim neo™ system, a second-generation system for delivering BAT.  Subjects were patients with resistant hypertension (SBP greater than or equal to 140 mm Hg despite treatment with 3 or more medications, including 1 ore more diuretic).  Stable medical therapy was required for 4 or more weeks before establishing pre-treatment baseline by averaging 2 SBP readings taken 24 or more hours apart.  A total of 30 patients enrolled from 7 medical centers in Europe and Canada.  From a baseline of 171.7 +/- 20.2/99.5 +/- 13.9 mm Hg, arterial BP decreased by 26.0 +/- 4.4/12.4 +/- 2.5 mm Hg at 6 months.  In a subset (n = 6) of patients with prior renal nerve ablation, arterial BP decreased by 22.3 +/- 9.8 mm Hg.  Background medical therapy for hypertension was unchanged during follow-up.  Three minor procedure-related complications occurred within 30 days of implant.  All complications resolved without sequelae.  The authors concluded that BAT delivered with the second-generation system significantly lowers BP in resistant hypertension with stable, intensive background medical therapy, consistent with studies of the 1st-generation system for electrical activation of the baroreflex, and provides a safety profile comparable to a pace-maker.  The findings of this small open-label study need to be validated by well-designed studies.

Jordan et al (2012) noted that recently, a novel implantable device was developed that produces an electrical field stimulation of the carotid sinus wall.  Carefully conducted experiments in dogs provided important insight in mechanisms mediating the depressor response to electrical carotid sinus stimulation.  Moreover, these studies showed that the treatment success may depend on the underlying pathophysiology of the hypertension.  The authors stated that clinical studies suggested that electrical carotid sinus stimulation attenuates sympathetic activation of vasculature, heart, and kidney while augmenting cardiac vagal regulation, thus lowering BP; however, not all patients respond to treatment.  They concluded that additional clinical trials are needed to ascertain the effectiveness of electrical carotid sinus stimulation in treatment resistant arterial hypertension.

Jordan et al (2013) stated that hypertension is the primary risk factor for cardiovascular and renal-disease endpoints.  Medications help many patients but not all.  Recently, 2 device-related treatments have been introduced, catheter-based renal denervation and electrical carotid sinus stimulation.  Remuneration for these treatments is guaranteed in many countries even though basic information is missing.  These investigators drew attention to deficiencies in the database.  For catheter-based renal denervation, few large-animal data are available to investigate the effect of the intervention on the histology of the arterial wall.  No functional data are available regarding re-innervation.  For carotid sinus stimulation, the situation is similar.  The authors concluded that acute activation of either treatment seems to reduce sympathetic tone dramatically; however, whether or not the effects are sustained over time is unknown.  They stated that no "end-point" data are available for either treatment, and devices should be subjected to evidence-based standards before widespread introduction.

Chobanyan-Jurgens et al (2015) stated that treatment-resistant arterial hypertension is associated with excess cardiovascular morbidity and mortality. Electrical carotid sinus stimulators engaging baroreflex afferent activity have been developed for such patients. Indeed, baroreflex mechanisms contribute to long-term BP control by governing efferent sympathetic and parasympathetic activity. The first-generation carotid sinus stimulator applying bilateral bipolar stimulation reduced BP in a controlled clinical trial but nevertheless failed to meet the primary efficacy end-point. The second-generation device utilizes smaller unilateral unipolar electrodes, thus decreasing invasiveness of the implantation while saving battery. An uncontrolled clinical study suggested improvement in BP with the second-generation device. The authors hoped that these findings as well as preliminary observations suggesting cardiovascular and renal organ protection with electrical carotid sinus stimulation will be confirmed in properly controlled clinical trials. Moreover, these researchers noted that it is important to find ways to better identify patients who are most likely to benefit from electrical carotid sinus stimulation.

Victor (2015) noted that arterial baroreceptors are mechano-sensitive sensory nerve endings in the walls of the carotid sinuses and aortic arch that buffer the increases and decreases in arterial BP. Electrical field stimulation of the carotid sinus, known as carotid baroreflex activation therapy, holds promise as a novel device-based intervention to supplement, but not replace, drug therapy for patients with resistant hypertension. Acute electrical field stimulation of even 1 carotid sinus can cause a sufficiently large reflex decrease in BP to overcome off-setting reflexes from the contralateral carotid baroreceptors and aortic baroreceptors that are not paced. However, the initial phase III Rheos Pivotal Trial on continuous carotid baroreceptor pacing for resistant hypertension with the first-generation baroreceptor pacemaker yielded equivocal data on efficacy and adverse effects due to facial nerve injury during surgical implantation. A miniaturized second-generation pacing electrode has seemingly overcome the safety issue, and early results with the new device suggested efficacy of unilateral carotid sinus stimulation in heart failure (HF). The authors stated that a phase III clinical trial of this new device for resistant hypertension has been registered.

Heusser and colleagues (2016) stated that bilateral bipolar electric carotid sinus stimulation acutely reduced muscle sympathetic nerve activity (MSNA) and BP in patients with resistant arterial hypertension; but is no longer available. The 2nd-generation device uses a smaller unilateral unipolar disk electrode to reduce invasiveness while saving battery life.  These researchers hypothesized that the 2nd-generation device acutely lowers BP and MSNA in treatment-resistant hypertensive patients.  In this study, a total of 18 treatment-resistant hypertensive patients (9 women/9 men; 53 ± 11 years; 33 ± 5 kg/m(2)) on stable medications have been included in the study.  These investigators monitored finger and brachial BP, HR, and MSNA.  Without stimulation, BP was 165 ± 31/91 ± 18 mm Hg, HR was 75 ± 17 bpm, and MSNA was 48 ± 14 bursts/min.  Acute stimulation with intensities producing side effects that were tolerable in the short-term elicited inter-individually variable changes in systolic BP (-16.9 ± 15.0 mm Hg; range of 0.0 to -40.8 mm Hg; p = 0.002), HR (-3.6 ± 3.6 bpm; p = 0.004), and MSNA (-2.0 ± 5.8 bursts/min; p = 0.375).  Stimulation intensities had to be lowered in 12 patients to avoid side effects at the expense of efficacy (systolic BP, -6.3 ± 7.0 mm Hg; range of 2.8 to -14.5 mm Hg; p = 0.028 and HR, -1.5 ± 2.3 bpm; p = 0.078; comparison against responses with side effects).  Reductions in diastolic BP and MSNA (total activity) were correlated (r(2) = 0.329; p = 0.025).  The authors concluded that in this patient cohort, unilateral unipolar electric baroreflex stimulation acutely lowered BP.  However, side effects may limit efficacy.  They stated that this approach should be tested in a controlled comparative study.

Wallbach and associates (2016) noted that BAT has been demonstrated to decrease office BP in the randomized, double-blind Rheos trial. There are limited data on 24-hour BP changes measured by ambulatory BP measurements (ABPMs) using the 1st generation Rheos BAT system suggesting a significant reduction but there are no information about the effect of the currently used, unilateral BAT neo device on ABPM.  In an observational study, ABPM was performed before BAT implantation and 6 months after initiation of BAT in patients treated with the BAT neo device for uncontrolled resistant hypertension.  A total of 51 patients were included in this study, 7 dropped-out from analysis because of missing or insufficient follow-up.  After 6 months, 24-hour ambulatory systolic (from 148 ± 17 mm Hg to 140 ± 23 mm Hg, p < 0.01), diastolic (from 82 ± 13 mm Hg to 77 ± 15 mm Hg, p < 0.01), day- and night-time systolic and diastolic BP (all p ≤ 0.01) significantly decreased while the number of prescribed anti-hypertensive classes could be reduced from 6.5 ± 1.5 to 6.0 ± 1.8 (p = 0.03); HR and pulse pressure remained unchanged.  Baroreflex activation therapy was equally effective in reducing ambulatory BP in all subgroups of patients.  The authors concluded that this was the first study demonstrating a significant BP reduction in ABPM in patients undergoing chronically stimulation of the carotid sinus using the BAT neo device.  About that BAT-reduced office BP and improved relevant aspects of ABPM, BAT might be considered as a new therapeutic option to reduce cardiovascular risk in patients with resistant hypertension.  Moreover, they stated that randomized controlled trials (RCTs) are needed to evaluate BAT effects on ABPM in patients with resistant hypertension accurately.

Jordan (2017) stated that device-based anti-hypertensive treatments have primarily been developed and clinically tested for patients with hypertension refractory to pharmacological treatment.  Most but not all device-based treatments target the sympathetic nervous system and provided important new insight in the mechanisms of human hypertension.  This investigator provided an overview on the scientific rational and clinical data on recent device-based anti-hypertensive treatment approaches.  Device-based treatments targeting the sympathetic nervous system include catheter-based renal nerve ablation, electrical carotid sinus stimulation, modulation of baroreflex transduction through a dedicated carotid stent, carotid body denervation, and deep brain stimulation.  Creation of a defined arterio-venous stent with a coupler device and removal of stimulatory antibodies against alpha adrenoreceptors have also been tested.  The author concluded that the clinical evidence differed from therapy to therapy with the largest data-set for renal nerve ablation followed by electrical carotid sinus stimulation; however, none has been proven effective in sham-controlled clinical trials, and none has been shown to reduce cardiovascular morbidity or mortality.  The author stated that before effectiveness is proven, these treatments should not be part of routine medical care and only be applied in the setting of clinical studies.

An assessment by the Ludwig Boltzmann Institute for Health Technology Assessment of baroreceptor activation therapy for treatment-resistant hypertension (Hawlick and Winkler, 2018) concluded that the quality of evidence was "very low."

Gierthmuehlen and colleagues (2020) presented an overview on recent developments in permanent implant-based therapy of resistant hypertension.  The American Heart Association (AHA) recently updated their guidelines to treat hypertension.  As elevated BP now is defined as a systolic BP of above 120 mmHg, the prevalence of hypertension in the U.S. has increased from 32 % (old definition of hypertension) to 46 %.  In the past years, device- and implant-mediated therapies have evolved and extensively studied in various patient populations.  Despite an initial drawback in a RCT of bilateral carotid sinus stimulation (CSS), new and less invasive and unilateral systems for BAT with the BAROSTIM NEO have been developed which show promising results in small non-RCTs.  Selective vagal nerve stimulation (VNS) has been successfully evaluated in rodents, but has not yet been tested in humans.  A new endovascular approach to re-shape the carotid sinus to lower BP (MobiusHD) has been introduced (baroreflex amplification therapy) with favorable results in non-RCT trials.  However, long-term results are not yet available for this therapeutic option.  A specific subgroup of patients, those with indication for a 2-chamber cardiac pacemaker, may benefit from a new stimulation paradigm which reduces the atrioventricular (AV) latency and thus limits the filling time of the left ventricle.  The most invasive approach for resistant hypertension still is the neuromodulation by deep brain stimulation (DBS), which has been shown to significantly lower BP in single cases.  The authors concluded that implant-mediated therapy remains a promising approach for the treatment of resistant hypertension.  Due to their invasiveness, such therapeutic options must prove superiority over conventional therapies with regard to safety and efficacy before they could be generally offered to a wider patient population.  Overall, BAROSTIM NEO and MobiusHD, for which large RCTs will soon be available, are likely to meet those criteria and may represent the first implant-mediated therapeutic options for hypertension, while the use of DBS probably will be reserved for individual cases.  The utility of VNS awaits appropriate assessment.

Wallbach et al (2023) stated that a relevant number of patients with resistant hypertension do not achieve blood pressure (BP) dipping during night-time.  This inadequate nocturnal BP reduction is associated with elevated cardiovascular risks.  In a prospective, observational study, these researchers examined if a night-time intensification of BAT might improve nocturnal BP dipping.  Non-dippers treated with BAT for at least 6 months were included.  BAT programming was modified in a 2-step intensification of night-time stimulation at baseline and week 6.  Twenty-four hours ABPMs were conducted at inclusion and after 3 months.  A total of 24 patients with non- or inverted-dipping pattern, treated with BAT for a median of 44 months (IQR 25 to 52) were included.  At baseline of the study, patients were 66 ± 9 years old, had a BMI of 33 ± 6 kg/m2 , showed an office BP of 135 ± 22/72 ± 10 mmHg, and took a median number of antihypertensives of 6 (inter-quartile range [IQR] 4 to 9).  Night-time stimulation of BAT was adapted by an intensification of pulse width from 237 ± 161 to 267 ± 170 μs (p = 0.003) while frequency (p = 0.10) and amplitude (p = 0.95) remained unchanged.  Up-titration of BAT programming resulted in an increase of systolic dipping from 2 ± 6 % to 6 ± 8 % (p = 0.03) accompanied with a significant improvement of dipping pattern (p = 0.02); and 24-hour ABPM, day- and night-time ABP remained unchanged.  The authors concluded that programming of an intensified night-time BAT interval improved dipping profile in patients treated with BAT, while the overall 24-hour ABP did not change.  These researchers stated that whether the improved dipping response would contribute to a reduction of cardiovascular risk beyond the BP-lowering effects of BAT, however, remains to be determined.

The authors stated that a main drawback of this study was the small number of patients (n = 24), which was the consequence of the current availability and diffusion of BAT in the treatment of resistant hypertension; thus, these findings should be interpreted with caution, especially with regard to the lack of significant changes.  In fact, these results might primarily serve for hypotheses-generation.  Larger studies are needed to confirm these data.  The study also lacked randomization, a control group, and blinding.  However, the apparently greater reduction in night-time BP in non‐dippers may be, at least in part, due to the effect of regression to the mean.  A prospective, randomized, sham‐controlled study examining BAT in patients with resistant hypertension using 24-hour ABP with nocturnal dipping status as secondary endpoint could overcome the afore-mentioned drawbacks.  Another relevant source for bias was the adherence to anti-hypertensive drugs.  This trial did not examine the impact of adherence to anti-hypertensive medication.  Changes in adherence might have influenced BP and dipping response throughout the study.  Another drawback was that no measures of indices of sympathetic activity, such as urinary catecholamines was carried out in this trial.

Magnetic Stimulation of Carotid Sinus

Zhang and colleagues (2017) evaluated the effectiveness of magnetic stimulation of carotid sinus (MSCS), a non-invasive strategy, for lowering BP in rabbits; MSCS with graded intensities and frequencies were systematically attempted in normotensive rabbits; BP was recorded dynamically.  Sino-aortic denervation and plasma hormone level analyses were performed.  When the right carotid sinus was stimulated at 1-Hz frequency, a dose-effect relationship was observed between stimulation intensity (100 to 250 % motor threshold) and mean arterial pressure (MAP) decrement (3.6 ± 1.0 to 10.4 ± 2.3 mmHg).  When stimulation intensity was fixed at 200 % motor threshold, the median reduction of MAP in 1-Hz group [10.8 (8.6 to 14.9) mmHg] was significantly higher than that in other frequency groups (all p < 0.05).  Heart rates declined transiently after the initiation of MSCS.  Compared with baseline, plasma epinephrine level increased during MSCS (from 33.9 ± 5.5 pg/ml  to 88.1 ± 9.6, p = 0.002).  After ipsilateral sino-aortic denervation, MAP decrement was remarkably blunted compared with that in sham animals (7.0 ± 0.8 mmHg  versus 13.0 ± 1.1 mmHg, p = 0.001).  The authors concluded that the findings of the current study demonstrated that MSCS treatment can lower the arterial pressure in normotensive rabbits.  They stated that is preliminarily finding warrants further studies to establish the effectiveness of MSCS in treating refractory hypertension.

Other Indications

Heart Failure

Georgakopoulos et al (2011) stated that heart failure with preserved ejection fraction (HFpEF) is a substantial public health issue, equal in magnitude to heart failure with reduced ejection fraction.  Clinical outcomes of HFpEF patients are generally poor, and no therapy has been shown to be effective in randomized clinical trials.  Baroreflex activation therapy (BAT) produced by stimulating the carotid sinuses using the Rheos device is being studied for the treatment of hypertension, the primary co-morbidity of HFpEF.  Other potential benefits include regression of left ventricular hypertrophy, normalization of the sympatho-vagal balance, inhibition of the renin-angiotensin-aldosterone system, arterio- and veno-dilation, and preservation of renal function.  The authors concluded that BAT may be a promising therapy for HFpEF and introduced the HOPE4HF trial, a randomized outcomes trial designed to evaluate the clinical safety and effectiveness of BAT in the HFpEF population.

The Institute for Clinical Systems Improvement's clinical practice guideline on "Heart failure in adults" (ICSI, 2011) did not mention the use of BAT.

An European Heart Rhythm Association’s report on "New devices in heart failure" (Kuck et al, 2014) stated that several new devices for the treatment of HF patients have been introduced and are increasingly used in clinical practice or are under clinical evaluation in either observational and/or randomized clinical trials.  These devices include cardiac contractility modulation, spinal cord stimulation, carotid sinus nerve stimulation, cervical vagal stimulation, intra-cardiac atrio-ventricular nodal vagal stimulation, and implantable hemodynamic monitoring devices.

Abraham et al (2015) stated that increased sympathetic and decreased parasympathetic activity contribute to heart failure (HF) symptoms and disease progression.  Baroreflex activation therapy (BAT) results in centrally mediated reduction of sympathetic outflow and increased parasympathetic activity.  In a clinical trial, these researchers examined the safety and effectiveness of carotid BAT in advanced HF.  Patients with New York Heart Association (NYHA) functional class III HF and ejection fractions (EFs) of 35 % or less on chronic stable guideline-directed medical therapy (GDMT) were enrolled at 45 centers in the U.S., Canada, and Europe.  They were randomly assigned to receive ongoing GDMT alone (control group) or ongoing GDMT plus BAT (treatment group) for 6 months.  The primary safety endpoint was system- and procedure-related major adverse neurological and cardiovascular events.  The primary efficacy endpoints were changes in NYHA functional class, quality-of-life (QOL) score, and 6-minute hall walk (6MHW) distance.  A total of 146 patients were randomized, 70 to control and 76 to treatment.  The major adverse neurological and cardiovascular event-free rate was 97.2 % (lower 95 % confidence bound 91.4 %).  Patients assigned to BAT, compared with control group patients, experienced improvements in the 6MHW distance (59.6 ± 14 m versus 1.5 ± 13.2 m; p = 0.004), QOL score (-17.4 ± 2.8 points versus 2.1 ± 3.1 points; p < 0.001), and NYHA functional class ranking (p = 0.002 for change in distribution).  BAT significantly reduced N-terminal pro-brain natriuretic peptide (p = 0.02) and was associated with a trend toward fewer days hospitalized for HF (p = 0.08).  The authors concluded that BAT was safe and improved functional status, QOL, exercise capacity, N-terminal pro-brain natriuretic peptide, and possibly the burden of HF hospitalizations in patients with GDMT-treated NYHA functional class III HF.  Moreover, these researchers stated that this latter observation should be confirmed in an adequately powered prospective outcome trial.

The authors stated that the relatively small number of patients studied may limit the interpretation of some of the results of this study.  Another potential limitation may be the lack of patient blinding and a sham control, leading to a “placebo effect” in the treatment arm, or a lack of blinding in investigator assessment of endpoints, leading to bias.  However, the magnitude of improvement in the primary endpoints was substantially larger than that attributable to such a placebo effect or bias in prior device trials.  For example, in prior studies of cardiac resynchronization therapy (CRT), the implantation of an inactive device was associated with a 10-m improvement in 6MHW distance, a placebo effect that fell far short of the nearly 60-m improvement observed with BAT in the present study.  Furthermore, at least 1 of the endpoints significantly improved by BAT, NT-proBNP, was not prone to a placebo effect.  The difference in follow-up schedule between study groups outside the United States (OUS) had the potential to bias the results.  However, there were no statistically significant differences in the treatment effect between the U.S. and OUS subjects.  Similarly, the differential collection of hospitalization data by world region could also introduce bias.

Weaver et al (2016) described the intra-operative experience along with long-term safety and effectiveness of the 2nd-generation BAT system in patients with HF and reduced EF HF (HFrEF).  In a randomized trial of NYHA Class III HFrEF, 140 patients were assigned 1:1 to receive BAT plus medical therapy or medical therapy alone.  Procedural information along with safety and effectiveness data were collected and analyzed over 12 months.  Within the cohort of 71 patients randomized to BAT, implant procedure time decreased with experience, from 106 ± 37 mins on the 1st case to 83 ± 32 mins on the 3rd case.  The rate of freedom from system- and procedure-related complications was 86 % through 12 months, with the percentage of days alive without a complication related to system, procedure, or underlying cardiovascular condition identical to the control group.  The complications that did occur were generally mild and short-lived.  Overall, 12 months therapeutic benefit from BAT was consistent with previously reported effectiveness through 6 months: there was a significant and sustained beneficial treatment effect on NYHA functional Class, QOL, 6MHW distance, plasma N-terminal pro-brain natriuretic peptide (NT-proBNP), and systolic blood pressure.  This was true for the full trial cohort and a pre-defined subset not receiving cardiac resynchronization therapy (CRT).  There was a rapid learning curve for the specialized procedures entailed in a BAT system implant.  The authors concluded that the BAT system implantation was safe with the therapeutic benefits of BAT in patients with HFrEF being substantial and maintained for at least 1 year.  These researchers stated that the level of evidence supporting BAT in HFrEF and the maturity of the 2nd-generation system indicated that the necessary conditions are in place for an outcomes trial.  They noted that a pivotal outcomes trial of BAT in HFrEF is expected to commence in 2016.

These investigators stated that although the phase-I and phase-II clinical trials both confirmed the long-term benefits of BAT in HFrEF, the present knowledge base needs to be expanded.  The phase-I trial was open-label and consisted of 11 patients whereas the phase-II trial consisted of 140 patients and used a medical management control group.  Therefore, the magnitude of benefit relative to sham was undetermined.  Reductions in muscle sympathetic nerve activity (phase-I) and NT-proBNP (phase-II) provided objective evidence that corroborated therapy benefit even in the absence of control.  Although these findings bode well for an outcomes trial, actual results should be accrued on a significant number of patients to confirm reductions in cardiovascular mortality and HF hospitalization.  This is the objective of a pivotal trial planned to begin enrollment in 2016.  Although the BAT system and implant techniques have evolved in a significantly positive direction from the 1t generation, opportunities for further improvement exist.  Because the most common electrode locations are known and 1 region in particular has become a de facto starting position for mapping, it is conceivable that an electrode could be developed to cover the locations where a response is most likely.  If anatomical landmarks coupled with a versatile electrode design were to obviate the need for mapping, not only would procedure time diminish, but also the complexity of anesthesia would be substantially reduced.  Furthermore, despite the fact that the suturing technique required to fix the BAT electrode is well within the capabilities of a vascular or cardiac surgeon, the process can be time-consuming.  If the number of required sutures could be reduced through a design change or the use of adjunctive fixatives or both, the procedure would also be simplified and shortened.  BAT is presently available for commercial use in resistant hypertension and HFrEF in regions that accept evidence commensurate with CE Marking.  Investigational plans are also in place to extend BAT availability for those conditions in the U.S.  Meanwhile, evidence suggested that BAT may be a useful treatment in chronic kidney disease, and HF with preserved EF.

In a systematic review, Schmidt et al (2020) examined the available data in the literature regarding the safety and effectiveness of BAT in the treatment of heart failure with reduced ejection fraction (HFrEF) patients.  These investigators searched electronic databases including PubMed, Embase, CENTRAL, Scopus, and Web of Science using Mesh and free terms for heart failure and BAT.  No language restriction was employed for the searches.  They included full peer-reviewed publications of clinical studies (randomized or not), including patients with HFrEF undergoing BAT, with or without control group, assessing safety and effectiveness outcomes.  One reviewer conducted the analysis of the selected abstracts and the full-text articles, carried out data extraction, and evaluated the methodological quality of the selected articles.  The methodological quality was examined according to the Cochrane Collaboration instruments.  A descriptive summary of the results was provided.  Of the 441 citations screened, 10 publications were included (3 were only conference abstracts), reporting data from 3 studies.  Only 1 study was a randomized clinical trial; 2 studies reported a 6-month follow-up, and the other study analyzed outcomes up to 41 months.  The procedure appeared to be safe when carried out by a well-trained, multi-professional team. An 86 % rate of system and procedure-related complication-free was reported, with no cranial nerve injuries.  Improvements were observed in NYHA class of HF, quality of life (QOL), 6 min walk test (6MWT), and hospitalization rates, as well as in muscle sympathetic nerve activity.  No meta-analysis was performed because of the lack of homogeneity across studies; the results from each study were reported individually.  The authors concluded that BAT procedure appeared to be safe if appropriate training is provided.  Improvements in clinical outcomes were described in all included studies; however, several limitations did not allow these investigators to make conclusive statements on the effectiveness of BAT for HFrEF.  They stated that further high‐quality RCTs with long‐term follow‐up are still needed to obtain conclusive results.

The authors stated that this study had several drawbacks.  Only 3 studies were available in the literature answering the review research question, and only 1 of them was designed as an RCT.  Furthermore, 3 of the 10 included publications were only abstracts published in conferences and not peer-reviewed publications.  The small sample size and the heterogeneity across the included studies lacked the power to make conclusive statements.  More importantly, these researchers designed their study as a rapid systematic review.  They performed all the steps of a traditional systematic review; however, they were executed by only 1 reviewer.  This approach has been previously described in the literature, and its value has been recognized by important organizations, such as the Cochrane Collaboration.  A rapid review has a shorten time of execution, making it possible to obtain results timely and with reduced costs.

Zile and colleagues (2020) examined the safety and effectiveness of BAT in patients with HF with reduced ejection fraction (HFrEF).  The BeAT-HF (Baroreflex Activation Therapy for Heart Failure) trial was a prospective, multi-center RCT; subjects were randomized 1:1 to receive either BAT plus optimal medical management (BAT group) or optimal medical management alone (control group).  A total of 4 patient cohorts were created from 408 randomized patients with HFrEF using the following enrollment criteria: current New York Heart Association (NYHA) functional class III or functional class II (patients who had a recent history of NYHA functional class III); EF of less than or equal to 35 %; stable medical management for greater than or equal to 4 weeks; and no Class I indication for cardiac re-synchronization therapy.  Effectiveness end-points were the change from baseline to 6 months in 6-min hall walk distance (6MHW), Minnesota Living with HF Questionnaire quality-of-life (QOL) score, and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels.  The safety end-point included the major adverse neurological or cardiovascular system or procedure-related event rate (MANCE).  Results from, timeline and rationale for, cohorts A, B, and C were presented in detail in the text.  Cohort D, which represented the intended use population that reflected the Food and Drug Administration (FDA)-approved instructions for use (enrollment criteria plus NT-proBNP of less than 1,600 pg/ml), consisted of 245 patients followed-up for 6 months (120 in the BAT group and 125 in the control group).  BAT was safe and significantly improved QOL, 6MHW, and NT-proBNP.  In the BAT group versus the control group, QOL score decreased (Δ = -14.1; 95 % confidence interval [CI]: -19 to -9; p < 0.001), 6MHW distance increased (Δ = 60 m; 95 % CI: 40 to 80 m; p < 0.001), NT-proBNP decreased (Δ = -25 %; 95 % CI: -38 % to -9 %; p = 0.004), and the MANCE-free rate was 97 % (95 % CI: 93 % to 100 %; p < 0.001).  The authors concluded that BAT was safe and significantly improved QOL, exercise capacity, and NT-proBNP.  Moreover, these researcher stated that further studies are needed to examine the impact of BAT on the frequency of hospitalization and mortality, and identify patients with HFrEF most likely to gain lasting benefit from this type of intervention.

The authors stated that this study had several drawbacks.  The BeAT-HF trial pre-market phase did not examine morbidity and mortality or change in cardiovascular structure or function end-points.  Data from previous studies suggested that the BAT-induced reduction in the NT-proBNP data of 25 % made it highly probable that morbidity and mortality would also be reduced, and that structural and functional re-modeling would occur with BAT.  For example, in the PARADIGM-HF (Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure) trial, morbidity and mortality were reduced when NT-proBNP fell by as little as 10 %, regardless of the treatment groups (sacubitril/valsartan versus enalapril).  The GUIDE-IT (Guiding Evidence Based Therapy Using Biomarker Intensified Treatment) trial suggested that reduction in NT-proBNP from greater than 1,000 to less than 1,000 pg/ml was associated with a significant improvement in LV systolic function (increased EF) and LV re-modeling (reduced LV end-diastolic volume).  However, all these specific end-points will require additional studies.   Heart failure hospitalization and cardiovascular mortality rates will be examined in the post-market phase of BeAT-HF.  Enrollment will continue as initially planned until a total of 480 patients have been randomized.  The post-market phase is intended to expand the indication of use to reduction of HF hospitalizations and cardiovascular mortality.  This post-market phase will be achieved when 320 mortal and morbid events have occurred.  A  supplemental pre-market approval will then be submitted to the FDA.  Moreover, these researchers noted that BeAT-HF was not a blinded trial; the control group did not have an implanted BAT device.  It was clearly acknowledged that 6MHW, QOL, NYHA functional class might be subject to placebo effects.  This was why the NT-proBNP data served a pivotal role in supporting the results of these patient-centered symptomatic end-points.

Furthermore, an UpToDate review on "Overview of the management of heart failure with reduced ejection fraction in adults" (Colucci, 2020) does not mention implantable carotid sinus stimulator as a management / therapeutic option.

Malangu et al (2021) noted that there has been significant interest in research for the development of device-based therapy as a therapeutic option of HF, whether it is with reduced or preserved EF.  This is due to the high morbidity and mortality rate in patients with HF despite recent advances in pharmacotherapies.  Following the success of cardiac re-synchronization therapy, baroreceptor activation therapy (BAT) has emerged as another novel device-based treatment for HF.  The Barostim neo was developed by CVRx (Minneapolis, MN) for the treatment of mild-to-severe HF.  The device works by electrically activating the baroreceptor reflex with the goal to restore the maladaptive autonomic imbalance that is observed in patients with HF.  The authors concluded that preliminary clinical investigations had given promising results with an encouraging safety profile.  Moreover, these researchers stated that BAT as a therapeutic option for HF is still investigational at this time.

The American College of Cardiology/American Heart Association/Heart Failure Society of America (ACC/AHA/HFSA)’s guideline for the management of heart failure (Heidenreich et al, 2022) stated that “Trials of device stimulation of the vagus nerve, spinal cord, and baroreceptors have had mixed responses.  An implantable device that electrically stimulates the baroreceptors of the carotid artery has been approved by the FDA for the improvement of symptoms in patients with advanced HF who are unsuited for treatment with other HF devices including CRT.  In a prospective, multicenter, RCT with a total of 408 patients with current or recent NYHA class III HF, LVEF ≤ 35%, baroreceptor stimulation was associated with improvements in QOL, exercise capacity, and NT-proBNP levels.  To date, there are no mortality or hospitalization rates results available with this device”.

Lindenfeld et al (2021) examined sex differences in the safety and effectiveness of BAT in the BeAT-HF (Baroreflex Activation Therapy for Heart Failure) Trial.  Patients were randomized 1:1 to receive GDMT alone (control group) or BAT plus GDMT.  Pre-specified subgroup analyses including change from baseline to 6 months in 6MWD, QOL assessed using the Minnesota Living with Heart Failure Questionnaire (MLWHQ), NYHA functional class, and NT-proBNP were conducted in men versus women.  A total of 53 women and 211 men were evaluated.  Women had similar baseline NT-proBNP levels, 6MWDs, and percentage of subjects with NYHA functional class III symptoms but poorer MLWHQ scores (mean of 62 ± 22 versus 50 ± 24; p = 0.01) compared with men.  Women experienced significant improvement from baseline to 6 months with BAT plus GDMT relative to GDMT alone in MLWHQ score (-34 ± 27 versus -9 ± 23, respectively; p < 0.01), 6MWD (44 ± 45 m versus -32 ± 118 m; p < 0.01), and improvement in NYHA functional class (70 % versus 27 %; p < 0.01), similar to the responses observed in men, with no significant difference in safety.  Women receiving BAT plus GDMT had a significant decrease in NT-proBNP (-43 % versus 7 % with GDMT alone; difference -48 %; p < 0.01), while in men this decrease was -15 % versus 2 %, respectively (difference -17 %; p = 0.08), with an interaction p value of 0.05.  The authors concluded that women in BeAT-HF had poorer baseline QOL than men but demonstrated similar improvements with BAT in 6MWD, QOL, and NYHA functional class.  Women had a significant improvement in NT-proBNP, whereas men did not.  These researchers stated that these preliminary findings were consistent with the response observed by sex to other GDMTs as well as CRT and suggested that women are likely to benefit from BAT at least as much as men.

The authors stated that the main drawback of this study was the small number of women (n = 53) enrolled in BeAT-HF relative to men, as these comparisons were not prospectively powered.  In many symptomatic domains (QOL score, exercise capacity, and functional status), women improved with BAT more than men; however, the difference was not statistically significant, and it was possible that these differences in response might become significant in larger trials.  In fact, the interaction p value between men and women became significant for QOL and NT-proBNP when the phase-2 data were included.  Women receiving BAT plus GDMT, however, had significant decreases in NT-proBNP between treatment groups from baseline to 6 months, whereas in men, the decrease was not significant, except when phase-2 data were included.  Although it is certainly possible that this difference may be spurious, NT-proBNP is a robust marker in this study, as it is both objective (in an unblinded trial) and a generally strong predictor of HF outcomes, as described.  These researchers stated that larger studies are needed to confirm this finding.  Finally, the BeAT-HF Trial thus far has not examined endpoints in morbidity and mortality or HF hospitalization; these are being studied in the now completed trial.  Because baseline sex differences were established in a host of patient-centered outcomes, this prompts questions regarding whether women who are more symptomatic may be more likely to be identified and enrolled in clinical trials with a novel therapy such as BAT.  Furthermore, these baseline differences appeared across multiple facets of distress, from HF symptoms to anxiety and depressive reports.  Fortunately, these baseline differences were not sustained across the course of the trial, and women experienced comparable benefits from the therapy.

Coates et al (2022) noted that heart failure with reduced ejection fraction (HFrEF) remains associated with high morbidity and mortality, poor QOL and significant exercise limitation.  Sympatho-vagal imbalance has been shown to predict adverse prognosis and symptoms in HFrEF, yet it has not been specifically targeted by any guideline-recommended device therapy to-date.  Barostim, which directly addresses this imbalance, is the 1st FDA-approved neuromodulation technology for the treatment of HFrEF.  In a meta-analysis, these investigators examined all randomized trial evidence to evaluate the effect of BAT on HF symptoms, QOL and NT-proBNP in patients with HFrEF.  An individual patient data (IPD) meta-analysis was carried out on all eligible studies that randomized HFrEF patients to BAT + GDMT or GDMT alone (open label).  Endpoints included 6-month changes 6MHW distance, Minnesota Living with Heart Failure (MLWHF) QOL score, NT-proBNP, and NYHA class in all patients and 3 subgroups.  A total of 554 randomized patients were included.  In all patients, BAT provided significant improvement in 6MHW distance of 49 m (95 % CI: 33 to 64), MLWHF QOL of -13 points (95 % CI: -17 to -10), and 3.4 higher odds of improving at least 1 NYHA class (95 % CI: 2.3 to 4.9) when comparing from baseline to 6 months.  These improvements were similar, or better, in patients who had baseline NT-proBNP of less than 1,600 pg/ml, regardless of the CRT indication status.  The authors concluded that an IPD meta-analysis suggested that BAT improved exercise capacity, NYHA class, and QOL in HFrEF patients receiving GDMT.  These clinically meaningful improvements were consistent across the range of studies.  BAT was also associated with an improvement in NT-proBNP in subjects with a lower baseline NT-proBNP.

These researchers stated that this IPD meta‐analysis included only 2 randomized trials and with a limited number of patients restricting the ability to observe subtle differences in responses between patient cohorts of interest.  Furthermore, both studies were open‐label, which may result in bias in the more subjective endpoints.  Nevertheless, the results were encouraging while they await longer term clinical outcomes from the 2nd post‐market phase of the BeAT‐HF Trial.

Babar and Giedrimiene (2022) noted that in the past 10 years, neuromodulation via BAT and VNS has emerged as an innovative approach for the treatment of HFrEF.  These investigators carried out a review of the literature to examine the safety and effectiveness on neuromodulation for the treatment of HFrEF.  Two independent researchers searched the PubMed, clinicaltrials.org, and the Cochrane databases for the most recent data on BAT and VNS published between 2013 and 2019; and a total of 9 studies were identified.  BAT and VNS therapy consistently improved subjective HF parameters including NYHA functional class and MLWHF Questionnaire.  Improvements in objective cardiac parameters such as left ventricular ejection fraction (LVEF) were less consistently observed; however, where present, ranged from +3 % to +6 %, in line with improvements observed after other guideline directed therapy such as left ventricular assist device (LVAD).  Benefits of BAT showed a predilection for patients without CRT and effectiveness of VNS therapy varied with device type.  The authors concluded that the clinical application of BAT and VNS was found to be limited due to low-powered data, inconsistencies in study design, short-term follow-up and lack of diversity in patient recruitment.  These researchers stated that well-powered studies with consistent design, longer follow-up and diverse populations are needed before BAT and VNS can be incorporated into HF guidelines and clinical practice.

Ahmed et al (2022) stated that treatment strategies that modulate autonomic tone via interventional and device-based therapies have been studied as an adjunct to pharmacotherapy of HFrEF.  In a meta-analysis, these investigators examined RCTs that assessed the effectiveness of device-based autonomic modulation for treatment of HFrEF.  All RCTs testing autonomic neuromodulation device therapy in HFrEF were included in this analysis.  Autonomic neuromodulation techniques included baroreflex activation (BRA), spinal cord stimulation (SCS), renal denervation (RD), and VNS.  The pre-specified primary endpoints included mean change and 95 % CI of LVEF, NT-proBNP, and QOL measures including 6-minute hall walk distance (6-MHWD), and MLHFQ.  NYHA functional class improvement was reported as odds ratios (ORs) and 95 % CI of improvement by at least 1 functional class.  A total of 8 studies were identified that included 1,037 participants (2 BRA, 1 SCS, 3 RD, and 2 VNS trials).  This included 6 open-label, 1 single-blind, and 1 sham-controlled, double-blind study.  The mean age (± SD) was 61 (± 9.3) years.  The mean follow-up time was 7.9 months; 20 % of the total patients were women, and the mean BMI (± SD) was 29.86 (± 4.12).  Autonomic neuromodulation device therapy showed a statistically significant improvement in LVEF (4.02 %; 95 % CI: 0.24 to 7.79), NT-proBNP (-219.80 pg/ml; 95 % CI: -386.56 to -53.03), NYHA functional class (OR 2.32; 95 % CI: 1.76 to 3.07), 6-MHWD (48.39 m; 95 % CI: 35.49 to 61.30), and MLHFQ (-12.20; 95 % CI: -19.24 to -5.16) compared to control.  The authors concluded that in patients with HFrEF, the use of autonomic neuromodulation device therapy was associated with improvement in LVEF, reduction in NT-proBNP, and improvement in patient-centered QOL outcomes in mostly small open-label trials.  Moreover, these researchers stated that large, double-blind, RCTs, or sham-controlled trials designed to detect differences in hard cardiovascular outcomes are needed before widespread use and adoption of autonomic neuromodulation device therapies in HFrEF.

---

References